SMARCB1 and cancer: Broader interrogation of the TCGA pan-cancer data (excluding BLCA) revealed that ~24% of tumors harbor deep or shallow deletions associated with low SMARCB1 mRNA expression (Supplementary Fig. 2F; Supplementary Data 5).